<div id="4q8we"></div>
<optgroup id="4q8we"></optgroup><nav id="4q8we"><tbody id="4q8we"></tbody></nav>
  • <legend id="4q8we"></legend>
  • <div id="4q8we"></div><button id="4q8we"><samp id="4q8we"></samp></button>
  • Skip to Content

    Clinical Trial News

    This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

    Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

    NEW YORK--(BUSINESS WIRE) November 23, 2020 -- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of...

    Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

    NEW YORK & MAINZ, Germany--(BUSINESS WIRE) December 02, 2020 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines...

    Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066

    HOUSTON, Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad...

    Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 30, 2020-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and...

    Novavax Announces COVID-19 Vaccine Clinical Development Progress

    GAITHERSBURG, Md., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for...

    Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2020-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and...

    Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2020-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and...

    FDA: Remdesivir (Veklury) Approval for the Treatment of COVID-19 - The Evidence for Safety and Efficacy

    November 25, 2020 -- Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of safety for the drug’s...

    Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of GM2 Gangliosidosis With PLX-300

    PARAMUS, N.J., Nov. 25, 2020 /PRNewswire/ -- Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage...

    RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

    LUND, Sweden, Nov. 25, 2020 /PRNewswire/ -- RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the...

    Second Interim Analysis of Clinical Trial Data Showed a 91.4% Efficacy for the Sputnik V Vaccine on Day 28 After the First Dose; Vaccine Efficacy is Over 95% 42 days After the First Dose

    The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days...

    GSK Starts Phase 3 Study of RSV Maternal Candidate Vaccine

    23 November 2020 -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase 3 clinical programme investigating the safety...

    AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19

    23 November 2020 Two different dosing regimens demonstrated efficacy with one showing a better profile No hospitalisations or severe cases of COVID-19 in...

    Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

    KENILWORTH, N.J.--(BUSINESS WIRE) November 16, 2020 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration...

    AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

    WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach...

    Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization

    TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab...

    FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate

    November 20, 2020 -- The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC)...

    Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives Interim Authorization from Health Canada as a Treatment for COVID-19

    INDIANAPOLIS, Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising...

    Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

    In addition to today’s submission to the FDA, the companies have already initiated rolling submissions across the globe including in Australia, Canada,...

    Baricitinib and Remdesivir Combination Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19

    INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug...

    View older articles

    More News Resources

    Subscribe to our Newsletter

    Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

    Further information

    Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

    246免费·天下彩